reports
- Stijn Demeester
Fagron/Expect a softer 1Q26, reiteration of FY guidance/BUY
We update our estimates with our c.6% higher Adj. EBITDA estimates for 2026F-28F largely driven by recent M&A's. We expect Fagron's trading update on 9 April to point to a somewhat softer quarter, reflecting temporary headwinds in the North American compounding segment. However, Fagron should reiterate its FY26 guidance of mid- to high-single digit organic revenue growth as growth should spring back in 2H26 as GLP1 headwinds fade. We reiterate our BUY recommendation and €27 per share target pric...
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Michiel Declercq
- Thibault Leneeuw
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
Dynamic Top Pick List Update April 2026: Adding Fagron
The tariff war between US and China has eased, but with the Iran conflict and an erratic Trump, uncertainty will continues unabated. Energy prices have gone ballistic, with gas prices doubling in Europe and has hit the cyclical stocks hard. KBC macro-econimists have hiked the inflation expectation for 2026 from 1.9% to 3.3%. While the macro-economic impact has been limited so far, a prolonged uncertain situation will result in economic damage. We continue our defensive stance in our Benelux Dyna...
FAGR FAGRON SA
WKL WOLTERS KLUWER NV
EVS EVS BROADCAST EQUIPMENT SA
UCB UCB S.A.
DIE D'IETEREN SA
SOF SOFINA SA
IBAB ION BEAM APPLICATIONS SA
ROYAL VOPAK NV
CSM CORBION NV
ABI ANHEUSER-BUSCH INBEV SA/NV
ARGX ARGEN-X SE
WDP WAREHOUSES DE PAUW SCA
AZE AZELIS GROUP NV
DEME DEME GROUP NV
SHUR SHURGARD SELF STORAGE LIMITED
Fagron increases share capital through exercise subscription rights
Fagron increases share capital through exercise subscription rights Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 31 March 2026 – 7PM CET Fagron increases share capital through exercise subscription rights Fagron announces that as a result of the exercise of subscription rights, 104,200 new shares have been issued on 31 March 2026. In accordance with the Belgian transparency legislation, Fagron notes that its total share capital currently amounts to € 507,462,601.84. The total number of shares with voting rights after the issue amounts to 73,773,104 which is also ...
Fagron verhoogt kapitaal door uitoefening van inschrijvingsrechten
Fagron verhoogt kapitaal door uitoefening van inschrijvingsrechten Gereglementeerde informatieNazareth (België)/Rotterdam (Nederland), 31 maart 2026 – 19:00u. CET Fagron verhoogt kapitaal door uitoefening van inschrijvingsrechten Fagron maakt bekend dat er op 31 maart 2026 104.200 nieuwe aandelen zijn uitgegeven als gevolg van de uitoefening van inschrijvingsrechten. Overeenkomstig de Belgische transparantiewetgeving deelt Fagron mee dat haar maatschappelijk kapitaal na de uitgifte € 507.462.601,84 bedraagt. Het totaal aantal stemrechtverlenende effecten na de uitgifte bedraagt 73.773.1...
- Jacob Mekhael
Galapagos Signs agreement with Gilead on T-cell Engager in autoimmune ...
Galapagos announced that, following Gilead entering into a definitive agreement to acquire Ouro Medicines for $1,675m in cash consideration, and up to $500m in contingent milestone payments, Galapagos and Gilead have now entered into a binding agreement to collaborate on advancing gamgertamig (BCMAxCD3 T cell engager) in autoimmune diseases. This agreement comes after the companies announced their advanced discussions on the collaboration last week. Economically, Galapagos is effectively co-fina...
- Guy Sips
- Jacob Mekhael
- Mathijs Geerts Danau
- Wim Lewi
Galapagos en Gilead gaan definitieve overeenkomst aan over samenwerkin...
Galapagos en Gilead gaan definitieve overeenkomst aan over samenwerking om een first-in-class T-cel-engagerprogramma voor auto-immuunziekten verder te ontwikkelen De nieuwe samenwerkingsstructuur levert aanzienlijk verbeterde financiële voorwaarden en flexibiliteit voor Galapagos op Na deze transactie blijft de Vennootschap over het grootste deel van haar liquide middelen beschikken voor bijkomende strategische transacties en andere prioriteiten van kapitaalallocatie Kans om met gamgertamig een potentieel first-in-class & best-in-class T-cell-engager in auto-immuunziekten te ontwikkelen ...
Galapagos and Gilead Enter into Binding Agreement to Collaborate on Ad...
Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases New collaboration structure achieves meaningfully improved financial terms and flexibility for Galapagos Following this transaction, the Company will continue to have a majority of its cash remaining for additional strategic transactions and other capital allocation priorities Opportunity to develop a potential first-in-class & best-in-class T cell engager in autoimmune diseases with gamgertamig Management to host conference call today, March 31, 20...
- Bruno Cavalier
- Luis de Toledo Heras
- Thomas Zlowodzki
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
UTDI UNITED INTERNET AG
EL ESSILORLUXOTTICA SA
PHA PHARMAGEST INTERACTIVE SA
FAGR FAGRON SA
BRBY BURBERRY GROUP PLC
KER KERING SA
BOSS HUGO BOSS AG
NANO NANOBIOTIX SA
01913 PRADA S.P.A.
AIXA AIXTRON SE
MLP MLP SE
PAT PATRIZIA AG
MONC MONCLER SPA
ENG ENAGAS SA
SMHN SUESS MICROTEC AG
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
TCH TECHNICOLOR SA
ZGN ERMENEGILDO ZEGNA NV
CTPNV CTP NV
DIA DISTRIBUIDORA INTERNACIONAL DE ALIMENTACION SA
- Bruno Cavalier
- Luis de Toledo Heras
- Thomas Zlowodzki
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
UTDI UNITED INTERNET AG
EL ESSILORLUXOTTICA SA
PHA PHARMAGEST INTERACTIVE SA
FAGR FAGRON SA
BRBY BURBERRY GROUP PLC
VETO VETOQUINOL SA
KER KERING SA
BOSS HUGO BOSS AG
NANO NANOBIOTIX SA
01913 PRADA S.P.A.
AIXA AIXTRON SE
MLP MLP SE
PAT PATRIZIA AG
MONC MONCLER SPA
ENG ENAGAS SA
SMHN SUESS MICROTEC AG
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
TCH TECHNICOLOR SA
ZGN ERMENEGILDO ZEGNA NV
DIA DISTRIBUIDORA INTERNACIONAL DE ALIMENTACION SA
- Robert Jan Vos
- Usama Tariq
Galapagos kondigt de voordracht aan van Gino Santini tot lid van de Ra...
Galapagos kondigt de voordracht aan van Gino Santini tot lid van de Raad van Bestuur De Raad van Bestuur is voornemens de heer Santini te benoemen tot Voorzitter, als opvolger van Jérôme Contamine, onder voorbehoud van zijn benoeming door aandeelhouders De heer Santini zal uitgebreide ervaring op het gebied van corporate governance, bedrijfsontwikkeling en leiderschap in de sector toevoegen aan de Raad van Bestuur Mechelen, België; 26 maart, 2026, 21:02 CET — Galapagos NV (Euronext & NASDAQ: GLPG), heeft vandaag bekendgemaakt dat Gino Santini is voorgedragen als Niet-Uitvoerend Onafhankel...
Galapagos Announces Nomination of Gino Santini to its Board of Directo...
Galapagos Announces Nomination of Gino Santini to its Board of Directors Subject to his election by shareholders, the Board intends to appoint Mr. Santini as Chair, succeeding Jérôme Contamine Mr. Santini will bring extensive corporate governance, business development and industry leadership experience to the Board Mechelen, Belgium; March 26, 2026, 21:02 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced the proposed appointment of Gino Santini as a Non-Executive Independent Director, with the intention to appoint him as Chair of its Board of Directors, subject to shareholder...
Galapagos Publishes 2025 Annual Report and Announces Annual and Extrao...
Galapagos Publishes 2025 Annual Report and Announces Annual and Extraordinary Shareholders’ Meetings Mechelen, Belgium; March 26, 2026, 21:01 CET; regulated information — Galapagos NV (Euronext & NASDAQ: GLPG) today published its annual report for the financial year 2025 and announced that its Annual Shareholders’ Meeting (AGM) and an Extraordinary Shareholders' Meeting (EGM) will be held sequentially on Tuesday, April 28, 2026 at 14:00 CET and 15:00 CET at Schaliënhoevedreef 20T, 2800 Mechelen, Belgium. The annual report for the financial year 2025, including a review of figures and perfo...
Galapagos publiceert 2025 jaarverslag en kondigt de Gewone (jaarlijkse...
Galapagos publiceert 2025 jaarverslag en kondigt de Gewone (jaarlijkse) en Buitengewone Algemene Vergaderingen aan Mechelen, België; 26 maart, 2026, 21:01 CET; gereglementeerde informatie — Galapagos NV (Euronext & NASDAQ: GLPG) heeft vandaag haar jaarverslag over het boekjaar 2025 gepubliceerd en aangekondigd dat haar Gewone (jaarlijkse) Algemene Vergadering (GAV) en een Buitengewone Algemene Vergadering (BAV) achtereenvolgens zullen plaatsvinden op dinsdag 28 april 2026 om 14.00 uur en 15.00 uur te Schaliënhoevedreef 20T, 2800 Mechelen, België. Het jaarverslag over het boekjaar 2025, inc...
- Jacob Mekhael
Hyloris FY25 results hold no major surprises
Hyloris reported FY25 results with a cash position of € 13.8m (YE24: € 23.6m), and revenue of € 7.2m (FY24: € 8.5m), driven by increased royalties but offset by lower milestone payments. Hyloris is yet to receive income related to commercialisation of Maxigesic IV in the US as the launch has been paused and restarted. The company did not provide specific cash runway guidance, but believes it has funding for development and strategic growth. € 6 TP and Hold maintained.
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Mathijs Geerts Danau
- Thomas Couvreur
- Wim Hoste
- Elias New
- Nicolas David
- Sinan Doganli
- Elias New
- Nicolas David
- Sinan Doganli
- Jacob Mekhael
Galapagos Advanced discussions with Gilead on potential collaboration
Galapagos announced that, following Gilead entering into a definitive agreement to acquire Ouro Medicines for $1,675m in cash consideration, and up to $500m in contingent milestone payments, Galapagos and Gilead are in advanced partnership discussions. Economically, Galapagos would effectively co-finance Gilead's acquisition and early-stage development of gamgertamig in return for royalties on net sales (20-23%) and freedom to go up to $500m (previously $150m) in the amended OLCA. In our view, t...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.